ADC Therapeutics sets IPO terms, to be valued at up to $1 billion

ADC Therapeutics S.A. ADCT, set terms of its initial public offering, as the Switzerland-based biotechnology company focused on cancer treatments looks to raise up to $185.3 million. ADC is offering 10,295,000 shares in the IPO, which is expected to price between $16 and $18.